Literature DB >> 20616538

Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.

Massimo Breccia1, Giuseppina Loglisci, Adriano Salaroli, Laura Cannella, Michelina Santopietro, Giuliana Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20616538     DOI： 10.1159/000314961

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  8 in total

1.  Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

Authors:  Matteo Molica; Adriano Salaroli; Giuliana Alimena; Massimo Breccia
Journal:  Blood Transfus       Date:  2013-04-15       Impact factor: 3.443

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

4.  Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase.

Authors:  Masayo Yamamoto; Hiroki Tanaka; Yasumichi Toki; Mayumi Hatayama; Satoshi Ito; Lynda Addo; Motohiro Shindo; Katsunori Sasaki; Katsuya Ikuta; Takaaki Ohtake; Mikihiro Fujiya; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2016-07-05       Impact factor: 2.490

5.  Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.

Authors:  Jong Wook Lee; Sung-Soo Yoon; Zhi Xiang Shen; Arnold Ganser; Hui-Chi Hsu; Ali El-Ali; Dany Habr; Nicolas Martin; John B Porter
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.

Authors:  Mathieu Meunier; Sarah Ancelet; Christine Lefebvre; Josiane Arnaud; Catherine Garrel; Mylène Pezet; Yan Wang; Patrice Faure; Gautier Szymanski; Nicolas Duployez; Claude Preudhomme; Denis Biard; Benoit Polack; Jean-Yves Cahn; Jean Marc Moulis; Sophie Park
Journal:  Oncotarget       Date:  2017-11-06

7.  Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Authors:  Harpreet Kochhar; Chantal S Leger; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2015-03-30

8.  Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes.

Authors:  Julia Stomper; Paulina Richter-Pechanska; Dietmar Pfeifer; Immacolata Andolfo; Achille Iolascon; Martina U Muckenthaler; Michael Lübbert
Journal:  Blood Adv       Date:  2022-06-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.